Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives
Biopharmaceutics & Drug Disposition · 2023-02 · 44 (1) · 26-47
DOI: 10.1002/bdd.2338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 16.11.2022. Verfasst von Akihiko Goto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics Research Laboratories, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, …. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Central Nervous System Diseases. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Considerable advances have been made in the research and development of oligonucleotide therapeutics (OTs) for treating central nervous system (CNS) diseases, such as psychiatric and neurodegenerative disorders, because of their promising mode of action. However, due to the tight barrier function and complex physiological structure of the CNS, the efficient delivery of OTs to target the brain has been a major challenge, and intensive efforts have been made to overcome this limitation. In this review, we summarize the representative methodologies and current knowledge of biodistribution, along with the pharmacokinetic/pharmacodynamic (PK/PD) relationship of OTs in the CNS, which are critical elements for the successful development of OTs for CNS diseases. First, quantitative bioanalysis methods and imaging‐based approaches for the evaluation of OT biodistribution are summarized. Next, information available on the biodistribution profile, distribution pathways, quantitative PK/PD modeling, and simulation of OTs following intrathecal or intracerebroventricular administration are reviewed. Finally, the latest knowledge on the drug delivery systems to the brain via intranasal or systemic administration as noninvasive routes for improved patient quality of life is reviewed. The aim of this review is to enrich research on the successful development of OTs by clarifying OT distribution profiles and pathways to the target brain regions or cells, and by identifying points that need further investigation for a mechanistic approach to generate efficient OTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics Research Laboratories, Preclinical and Translational Sciences, Research, Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa, Japan.
ORCID-Profile: Akihiko Goto, Shinji Iwasaki
Zitieren
APA
Goto, A., Yamamoto, S., & Iwasaki, S. (2023). Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives. Biopharmaceutics & Drug Disposition, 44(1), 26-47. https://doi.org/10.1002/bdd.2338
Vancouver
Goto A, Yamamoto S, Iwasaki S. Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives. Biopharmaceutics & Drug Disposition. 2023;44(1):26-47. doi:10.1002/bdd.2338
BibTeX
@article{Goto2023,
author = {Goto, Akihiko and Yamamoto, Syunsuke and Iwasaki, Shinji},
title = {Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
volume = {44},
number = {1},
pages = {26--47},
doi = {10.1002/bdd.2338}
}
EUVIMED